flosz schreef op 4 april 2011 15:51:
Michiel Lodder naar Pepscan:
LELYSTAD, The Netherlands, April 4, 2011 /PRNewswire/ -- Pepscan Therapeutics, the Dutch biotech company focusing on protein mimicry for the discovery of therapeutics peptides and antibodies, announced today the appointment of Michiel Lodder as Chief Business Officer. Dr. Lodder joins Pepscan from Octoplus, where he held the position of Senior Manager Business Development, responsible for licensing, partnering, and alliance management activities.
"We are delighted to bring Michiel Lodder on board to help us exploit the enormous potential of Pepscan's pioneering CLIPS platform for the discovery and development of therapeutic peptides and antibodies," said Wim Mol, CEO of Pepscan. "Pepscan has recently established a number of research collaboration and licensing agreements with major pharma and biotech companies, and Michiel's business savvy and deal-making experience make him ideal to further expand our partnership base."
"I'm very excited to join the company at this pivotal stage," stated Lodder. "The potential of the CLIPS technology to significantly improve therapeutic peptide leads or generate antibodies against intractable targets such as GPCR's and ion channels is far-reaching. Through successful partnering Pepscan can play an important role in the advancement of innovative peptide and antibody therapeutics."
Michiel Lodder holds a M.Sc. in Organic Chemistry from the University of Leiden, and a PhD in Bio-Organic Chemistry from the University of Virginia in Charlottesville, VA. Throughout his career in corporate business development, he contributed or delivered numerous strategic partnerships and license deals encompassing technology platform and product deals. In his role as Director Business Development, North America he was responsible for the establishment and management of OctoPlus Inc., located in Cambridge, MA, USA
tinyurl.com/3eyg4m6